A
federal appeals court ruled on Tuesday that biosimilar makers must always notify their brand-name rivals six months before launching their lower-cost versions of expensive biologic medicines. The decision may have a significant impact on near-term health care costs, because it will effectively delay competition for these pricey drugs.
Although the same court has previously decided this overarching issue, the latest decision actually turned on a related interpretation of the same federal law that governs the complex procedures biosimilar makers must follow as they seek to market their lower-cost medicines.
This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.
About the Author
